Section Review Group | Appendix B: Panel Roster and Financial Disclosures | Adult and Adolescent Opportunistic Infection | ClinicalInfo

Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

Updated

Jan. 01, 2020

Reviewed

Jan. 01, 2020

Appendix B: Panel Roster and Financial Disclosures

Section Review Group

Section Review Group
Member		Financial Disclosure
Member		Company	Relationship
Barakat, Lydia	Yale University School of Medicine	None	N/A
Campbell, Thomas*	University of Colorado Denver School of Medicine	Gilead Sciences	Advisory Board, Research Support
		Janssen	Research Support
		Merck	Advisory Board
		ViiV	Advisory Board, Research Support
Healey, Letha	HIV/AIDS Bureau Health Resources and Services Administration	None	N/A
Kitchell, Ellen	University of Texas Southwestern	None	N/A
Robbins, Gregory	Massachusetts General Hospital	AIDS Clinical Trial Group (ACTG)	Research Support
		Biogen	Equity Interest
		Citius Pharmaceuticals	Research Support
		Emergent Biosolutions	Research Support
		Gilead Sciences	Research Support
		Leonard Meron Biosciences	Research Support
		Pfizer	Research Support
		United Healthcare	Equity Interest
* Group lead Note: Members were asked to disclose all relationships from 12 months prior to the reviewed date. The period of reporting was from January 1, 2019, through January 1, 2020.

Download Guidelines

Section OnlyPDF (337.79 KB)
Full GuidelinePDF (3.78 MB)
Tables OnlyPDF (481.21 KB)